Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Let's have a look at the gap up and gap down stocks in today's session.

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Shares of Tonix Pharmaceuticals have rallied 30% over the past five sessions. Investors are anticipating a key catalyst for the company.

Shares of Tonix Pharmaceuticals are building on recent gains. The stock is trading higher as investor focus intensifies on a key, upcoming catalyst.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Shares of Tonix Pharmaceuticals are trading sharply higher Tuesday morning. The stock is gaining following the release of the company's Q2 financial results and operational update.

Tonix Pharmaceuticals has filed a registration statement to sell up to $500 million in securities. The company's lead drug candidate is for the management of fibromyalgia pain.

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

The proceeds from the purchase agreement are expected to be used for working capital and general corporate purposes.

Tonix Pharmaceuticals Corp. (NASDAQ:TNXP) shares have nearly doubled over the past month. Here's what you need to know.